Compare · BIO vs HBIO
BIO vs HBIO
Side-by-side comparison of Bio-Rad Laboratories Inc. (BIO) and Harvard Bioscience Inc. (HBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIO and HBIO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $7.95B, about 291.9x HBIO ($27.2M).
- Over the past year, BIO is up 29.3% and HBIO is up 5.5% - BIO leads by 23.8 points.
- HBIO has hit the wire 2 times in the past 4 weeks while BIO has been quiet.
- BIO has more recent analyst coverage (12 ratings vs 2 for HBIO).
- Company
- Bio-Rad Laboratories Inc.
- Harvard Bioscience Inc.
- Price
- $297.38+2.07%
- $6.20-3.58%
- Market cap
- $7.95B
- $27.2M
- 1M return
- +16.91%
- -11.43%
- 1Y return
- +29.27%
- +5.46%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1980
- 2000
- News (4w)
- 0
- 2
- Recent ratings
- 12
- 2
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Harvard Bioscience Inc.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. The company also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products, systems, services, and solutions with a focus on physiologic monitoring solutions. It markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. The company primarily sells its products under Harvard Apparatus, Biochrom, Hoefer, Panlab, Warner Instruments, Hugo Sachs Elektronik, Scie-Plas, BTX, Multi Channel Systems, HEKA, DSI, Ponemah, and Buxco brand names in North America, Europe, China, and internationally. Harvard Bioscience, Inc. was founded in 1901 and is headquartered in Holliston, Massachusetts.
Latest BIO
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
- Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
- Bio-Rad Reports Third-Quarter 2025 Financial Results
- Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
Latest HBIO
- Harvard Bioscience Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form SD filed by Harvard Bioscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Harvard Bioscience Inc.
- SEC Form 10-Q filed by Harvard Bioscience Inc.
- Harvard Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Harvard Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Harvard Bioscience Announces First Quarter 2026 Financial Results
- Harvard Bioscience to Participate in Upcoming Investor Conferences
- Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
- SEC Form DEFA14A filed by Harvard Bioscience Inc.